80 results found. Viewing page 3 of 16.
Go to page . . .
-
Posted By
Dr. Thomas Royer
This is the first blog of a three-part series on MACRA, Medicare’s new payment system for physicians. In it, we describe the realities of MACRA for providers. These are significant and somewhat over-whelming for many. Part 2 will be “MACRA – The Critical Success Factors”, followed by Part 3 “MACRA - The Toxic Side Effects”. In the most simplistic terms, MACRA ...
Continue Reading
-
Posted By
Jay Herron
Dr. Royer and I had a very interesting meeting with leadership from the company, Vestagen. The company produces high performance apparel for healthcare workers. The apparel has several unique qualities. “Vestagen’s VESTEX fabric has robust liquid repellency and antimicrobial properties, along with breathability, comfort and durability.” I will be the first to admit I’m not ...
Continue Reading
-
Posted By
Dr. Thomas Royer
The Latin “Primum non nocere”, which translates to “first, do no harm”, has been a guiding principle for physicians since the beginning of time. It means that whatever the intervention or procedure, the patient’s well-being is the primary consideration. Although this phase is not in the Hippocratic Oath which nearly 100% of physicians swear to on graduation from ...
Continue Reading
-
Posted By
Dr. Thomas Royer
Most leaders in health care today know that physicians are the significant driver of the quality and costs associated with medical care. Because today payment reform is being driven by the value equation, the traditional roles providers have played in the past must be transformed. These transformations are requiring changes in practice style and focus, which many of the older physicians are ...
Continue Reading
-
Posted By
Dr. Thomas Royer
Recently I was asked to present at the annual meeting of the MDMA – The Medical Device Management Association. The program committee requested that I speak about the most significant changes over the last five years and what I am forecasting for the next five years. In addition, they indicated the audience of device inventors, investors, and regulators from CMS and the FDA, would be ...
Continue Reading
80 results found. Viewing page 3 of 16.
Go to page . . .